Roy Fleischmann

32.1k total citations · 15 hit papers
347 papers, 22.9k citations indexed

About

Roy Fleischmann is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Roy Fleischmann has authored 347 papers receiving a total of 22.9k indexed citations (citations by other indexed papers that have themselves been cited), including 298 papers in Rheumatology, 151 papers in Hematology and 94 papers in Genetics. Recurrent topics in Roy Fleischmann's work include Rheumatoid Arthritis Research and Therapies (267 papers), Autoimmune and Inflammatory Disorders Research (151 papers) and Systemic Lupus Erythematosus Research (96 papers). Roy Fleischmann is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (267 papers), Autoimmune and Inflammatory Disorders Research (151 papers) and Systemic Lupus Erythematosus Research (96 papers). Roy Fleischmann collaborates with scholars based in United States, Germany and United Kingdom. Roy Fleischmann's co-authors include Michael Schiff, Joel M. Kremer, Mark C. Genovese, Ronald van Vollenhoven, Larry W. Moreland, Edward Keystone, Michael E. Weinblatt, David Gruben, Gene V. Wallenstein and Désirée van der Heijde and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Roy Fleischmann

335 papers receiving 22.0k citations

Hit Papers

A Trial of Etanercept, a Recombinant Tumor Necrosis Facto... 1997 2026 2006 2016 1999 2000 1997 2012 2006 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
    1999 1.6k citations Michael E. Weinblatt, Roy Fleischmann et al. profile →
  2. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
    2000 1.4k citations Roy Fleischmann, John Tesser et al. profile →
  3. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein
    1997 1.3k citations Larry W. Moreland, Michael Schiff et al. profile →
  4. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
    2012 790 citations Roy Fleischmann, Carol A. Connell et al. profile →
  5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
    2006 783 citations Paul Emery, Roy Fleischmann et al. Arthritis & Rheumatism profile →
  6. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
    2012 739 citations Ronald van Vollenhoven, Roy Fleischmann et al. profile →
  7. Tofacitinib versus Methotrexate in Rheumatoid Arthritis
    2014 598 citations Roy Fleischmann, Stephen Hall et al. profile →
  8. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
    2003 583 citations Désirée van der Heijde, Maxime Dougados et al. Arthritis & Rheumatism profile →
  9. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
    2002 573 citations Mark C. Genovese, Roy Fleischmann et al. Arthritis & Rheumatism profile →
  10. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Désirée van der Heijde, Roy Fleischmann et al. Arthritis & Rheumatism profile →
  11. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
    2013 366 citations Zhanguo Li, Stephen Hall et al. Annals of Internal Medicine profile →
  12. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
    2018 331 citations Mark C. Genovese, Roy Fleischmann et al. The Lancet profile →
  13. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
    2019 329 citations Roy Fleischmann, Eduardo Mysler et al. Arthritis & Rheumatology profile →
  14. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
    2016 309 citations Roy Fleischmann, Michael Schiff et al. Arthritis & Rheumatology profile →
  15. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
    2024 58 citations Zoltán Szekanecz, Christina Charles‐Schoeman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roy Fleischmann United States 69 16.7k 8.1k 6.4k 3.9k 2.8k 347 22.9k
Mark C. Genovese United States 76 14.1k 0.8× 6.5k 0.8× 8.5k 1.3× 3.5k 0.9× 3.4k 1.2× 317 22.7k
Edward Keystone Canada 69 17.0k 1.0× 7.8k 1.0× 6.8k 1.1× 4.2k 1.1× 2.0k 0.7× 404 24.5k
Ronald van Vollenhoven Sweden 80 20.6k 1.2× 6.8k 0.8× 10.0k 1.6× 4.4k 1.1× 2.8k 1.0× 512 27.7k
Ferdinand C. Breedveld Netherlands 67 15.2k 0.9× 5.4k 0.7× 5.4k 0.8× 2.6k 0.7× 2.3k 0.8× 182 21.9k
Daniel Aletaha Austria 64 15.0k 0.9× 5.4k 0.7× 4.7k 0.7× 2.4k 0.6× 1.9k 0.7× 327 21.2k
Ben A. C. Dijkmans Netherlands 83 18.3k 1.1× 6.1k 0.8× 6.3k 1.0× 2.1k 0.5× 1.9k 0.7× 332 25.0k
Stanley Cohen United States 61 10.5k 0.6× 4.7k 0.6× 4.5k 0.7× 2.3k 0.6× 3.9k 1.4× 214 18.4k
E. William St. Clair United States 55 9.1k 0.5× 3.2k 0.4× 5.3k 0.8× 2.3k 0.6× 1.2k 0.4× 170 16.5k
Harvinder S. Luthra United States 34 13.7k 0.8× 3.6k 0.4× 4.8k 0.8× 1.7k 0.4× 1.9k 0.7× 96 20.4k
Munther A. Khamashta United Kingdom 84 22.6k 1.4× 8.7k 1.1× 10.1k 1.6× 1.1k 0.3× 1.7k 0.6× 411 31.3k

Countries citing papers authored by Roy Fleischmann

Since Specialization
Citations

This map shows the geographic impact of Roy Fleischmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Fleischmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Fleischmann more than expected).

Fields of papers citing papers by Roy Fleischmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Fleischmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Fleischmann. The network helps show where Roy Fleischmann may publish in the future.

Co-authorship network of co-authors of Roy Fleischmann

This figure shows the co-authorship network connecting the top 25 collaborators of Roy Fleischmann. A scholar is included among the top collaborators of Roy Fleischmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy Fleischmann. Roy Fleischmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Weinblatt, Michael E., Peter C. Taylor, Iain B. McInnes, et al.. (2025). Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X). BMJ Open. 15(3). e088869–e088869. 1 indexed citations
3.
4.
Charles‐Schoeman, Christina, Roy Fleischmann, Eduardo Mysler, et al.. (2024). Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients. Arthritis & Rheumatology. 76(8). 1218–1229. 13 indexed citations
5.
Feist, Eugen, Roy Fleischmann, Saeed Fatenejad, et al.. (2024). Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Annals of the Rheumatic Diseases. 83(11). 1454–1464. 3 indexed citations
6.
7.
Wei, James Cheng‐Chung, Roy Fleischmann, Shannon R. Morris, et al.. (2023). OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS. Annals of the Rheumatic Diseases. 82. 192–192. 5 indexed citations
8.
Fleischmann, Roy, et al.. (2022). Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. Rheumatology and Therapy. 9(2). 649–661. 1 indexed citations
9.
Kerschbaumer, Andreas, Josef S Smolen, Peter Nash, et al.. (2020). Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 6(3). e001374–e001374. 44 indexed citations
10.
Helliwell, P, Éric Lespessailles, Catherine L Shuler, et al.. (2018). Ixekizumab Provides Sustained Improvement In Signs And Symptoms In Patients With Active Psoriatic Arthritis: Two Year Results From A Phase 3 Trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 1 indexed citations
11.
Kloppenburg, M., Charles Peterfy, I.K. Haugen, et al.. (2018). Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases. 78(3). 413–420. 130 indexed citations
12.
Heijde, Désirée van der, Atul Deodhar, Oliver FitzGerald, et al.. (2018). 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 4(1). e000582–e000582. 30 indexed citations
13.
Mease, Philip J., Roy Fleischmann, J. Wollenhaupt, et al.. (2016). CERTOLIZUMAB PEGOL FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA TRIAL. Clinical and Experimental Rheumatology. 34(4). 779–780. 2 indexed citations
14.
Fleischmann, Roy, Andrew Koenig, Annette Szumski, et al.. (2014). Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Lara D. Veeken. 53(11). 1984–1993. 13 indexed citations
15.
16.
Kremer, Joel, Zhanguo Li, Stephen Hall, et al.. (2013). Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. Annals of Internal Medicine. 5 indexed citations
17.
Smolen, Josef S, Michael Schiff, Roy Fleischmann, et al.. (2010). SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA). Lara D. Veeken. 49. 5 indexed citations
18.
Fleischmann, Roy. (2009). Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis & Rheumatism. 60(11). 3225–3228. 89 indexed citations
19.
Emery, Paul, et al.. (2009). Paediatric and Adolescent Rheumatology [213-214]. Lara D. Veeken. 48(Supplement 1). i93–i94. 1 indexed citations
20.
Tesser, John, Roy Fleischmann, Robin K. Dore, et al.. (2004). Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.. PubMed. 31(4). 649–54. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark C. Genovese Breakdown of academic impact, for papers by Edward Keystone Breakdown of academic impact, for papers by Ronald van Vollenhoven Breakdown of academic impact, for papers by Ferdinand C. Breedveld Breakdown of academic impact, for papers by Daniel Aletaha Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Stanley Cohen Breakdown of academic impact, for papers by E. William St. Clair Breakdown of academic impact, for papers by Harvinder S. Luthra Breakdown of academic impact, for papers by Munther A. Khamashta
Rankless by CCL
2026